Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20153224 | 0.92 | RET (0.37) | HRH3PIK3CDRETCCR2TYK2 | |
| SCHEMBL20148738 | 0.88 | CCR2 (0.36) | HRH3CCR2L3MBTL1 | |
| SCHEMBL20153223 | 0.85 | RET (0.36) | HRH3PIK3CDRETCCR2L3MBTL1 | |
| SCHEMBL22812230 | 0.81 | KAT2B (0.35) | PIK3CDRETCCR2TYK2JAK3 | |
| SCHEMBL20070811 | 0.81 | RET (0.36) | HRH3PIK3CDRETCCR2L3MBTL1 | |
| SCHEMBL20149640 | 0.81 | ATM (0.41) | PIK3CDRETCCR2TYK2JAK3 | |
| SCHEMBL23126245 | 0.81 | RET (0.36) | PIK3CDRETCCR2TYK2JAK3 | |
| SCHEMBL21159102 | 0.78 | RET (0.33) | RETTYK2JAK3 | |
| SCHEMBL20070420 | 0.77 | PIK3CD (0.49) | HRH3PIK3CDRETCCR2 | |
| SCHEMBL21695511 | 0.77 | RET (0.38) | RETCCR2TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| EP-3523301-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HRH3 1148/4885PIK3CD 1191/4885RET 1/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HRH3 1148/4885PIK3CD 1191/4885RET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.